NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Tuesday that it has revised its co-marketing deal with Precision Therapeutics.

Under the revised terms, reached on Oct. 11, Rosetta grants Precision co-exclusive rights to market the miRview mets2 assay in the US. Once a minimum number of tests ordered through Precision is reached in a given month, Rosetta will pay Precision a flat monthly fee, a Rosetta spokesperson said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.